USAID Funding Cuts Leave Sokoto Malaria Treatment Crisis: Soaring Drug Costs, Missing Tests, and Collapsed Data Collection

USAID funding cuts have increased the price of malaria medications and eliminated supplies of rapid diagnostic tests in Sokoto, Nigeria, according to a June 16, 2026, report by Forbes. The reduction in international aid has also caused a sharp decline in malaria data collection across the state.

The funding withdrawal affects the Sokoto State Malaria Elimination Agency, which relies on external support to maintain drug inventories and diagnostic capabilities. The loss of these subsidies has shifted the financial burden of malaria treatment to local providers and patients.

Why are malaria drugs more expensive in Sokoto?

The cost of malaria treatments rose after USAID reduced its financial contributions to the region. According to Forbes, these cuts removed the subsidies that previously kept the price of essential medications low for the general population.

In Nigeria, malaria treatment typically relies on Artemisinin-based combination therapies (ACTs). These drugs are often procured through international partnerships like the U.S. President’s Malaria Initiative (PMI), a USAID-led program. When these funds are cut, the state must pivot to private procurement or higher-cost local alternatives.

The price increase creates a barrier for low-income residents in Sokoto, where malaria remains a primary cause of morbidity. Without subsidized ACTs, patients are more likely to seek cheaper, less effective monotherapies or delay treatment entirely.

What happened to diagnostic testing and data collection?

Sokoto has completely run out of rapid diagnostic tests (RDTs) following the USAID funding cuts, Forbes reports. RDTs allow healthcare workers to confirm a malaria diagnosis in minutes without a microscope.

The absence of these tests leads to “presumptive treatment,” where clinicians prescribe malaria drugs based on symptoms like fever alone. This practice increases the risk of misdiagnosing other febrile illnesses and contributes to drug resistance.

Data collection has also plummeted in the state. The Sokoto State Malaria Elimination Agency uses this data to track infection hotspots and allocate resources. The Forbes report indicates that the loss of funding has crippled the systems used to report cases and outcomes.

Without accurate data, the agency cannot determine if malaria rates are rising or falling, making it difficult to secure new grants or justify state budget increases for healthcare.

How is the Sokoto State Malaria Elimination Agency responding?

The agency is currently attempting to manage the gap left by USAID. The transition highlights a broader trend in international development where donor agencies shift from direct service provision to “sustainability” models, requiring local governments to fund their own health initiatives.

The current situation in Sokoto contrasts with previous years of PMI support, which focused on the mass distribution of insecticide-treated nets and the provision of free RDTs. The suddenness of the supply exhaustion suggests that local procurement systems were not prepared to replace the USAID pipeline.

The agency’s struggle to maintain basic diagnostics and data tracking creates a cycle of instability. As data collection drops, the evidence needed to attract new international partners or private investors diminishes.

The impact on the business of healthcare in the region is immediate. Private pharmacies are now the primary source for malaria drugs, but their pricing is subject to market volatility and import costs, further alienating the poorest patients.

• Malaria drug costs have increased due to the loss of USAID subsidies.
• Rapid diagnostic tests (RDTs) are currently unavailable in the state.
• Case tracking and health data collection have seen a significant decline.
• The Sokoto State Malaria Elimination Agency is the primary entity affected by these funding shifts.